case_images: PMC10621037_01
case_images: Changes in hematologic parameters from D + 86 (May 5, 2022) to D + 369 (February 8, 2023).
case_images: fmed-10-1224179-g002.jpg
case_images: PMC10621037_01_fmed-10-1224179-g002.jpg
case_images: fig2
case_images: Changes in routine blood and CSF testing are shown in Figures 2, 3 (the detailed data were listed in Tables S1, S2 in Supplementary material).
case_images: Changes in routine CSF testing from D + 90 (May 5, 2022) to D + 369 (February 8, 2023).
case_images: fmed-10-1224179-g003.jpg
case_images: PMC10621037_01_fmed-10-1224179-g003.jpg
case_images: fig3
case_images: Changes in routine blood and CSF testing are shown in Figures 2, 3 (the detailed data were listed in Tables S1, S2 in Supplementary material).
case_images: Unenhanced brain MRI scan on April 19, 2022(D + 74): Multiple infarcts and ischemic foci were seen bilaterally in the periventricular and frontoparietal white matter; there were abnormally enhancing lesions in the right ambient cistern, left sylvian cistern and adjacent brain parenchyma, which was considered a diagnosis of TBM, especially by referring to her medical history; also there was mild brain atrophy.
case_images: fmed-10-1224179-g004.jpg
case_images: PMC10621037_01_fmed-10-1224179-g004.jpg
case_images: fig4
case_images: Tryptophan test: negative; The patient generally improved and her weight increased by about 10 kg. Her diet, sleep, urine, and defecation were regular. Apart from an intermittent numbness of both lower extremities, which became milder than before, the patient had no other complaints of adverse symptoms. The patient's initial anti-TB treatment course was 12 months, of which she received contezolid for about eight months. The relevant follow-up indices were stable, and we continue to recommend that she have regular follow-up visits after stopping the anti-TB drugs. The contrast-enhanced MRI of the brain showed continued improvement (Figures 4, 5).
case_images: Follow-up unenhanced brain MRI scan on February 10, 2023(D + 371): The abnormally enhancing lesions in the right ambient cistern, left sylvian cistern, and adjacent brain parenchyma have improved.
case_images: fmed-10-1224179-g005.jpg
case_images: PMC10621037_01_fmed-10-1224179-g005.jpg
case_images: fig5
case_images: Tryptophan test: negative; The patient generally improved and her weight increased by about 10 kg. Her diet, sleep, urine, and defecation were regular. Apart from an intermittent numbness of both lower extremities, which became milder than before, the patient had no other complaints of adverse symptoms. The patient's initial anti-TB treatment course was 12 months, of which she received contezolid for about eight months. The relevant follow-up indices were stable, and we continue to recommend that she have regular follow-up visits after stopping the anti-TB drugs. The contrast-enhanced MRI of the brain showed continued improvement (Figures 4, 5).